Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4618 - Efficacy and safety profile of the Adriamycin/ Cyclophosphamide (AC)followed by Docetaxel/Cisplatin(DC) in locally advanced breast cancer

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Breast Cancer

Presenters

Thoraya Abdelhamid

Citation

Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364

Authors

T. Abdelhamid1, M. Saber1, A. Abdel-Samie Gaber1, M. Selim1, O. Youssef2, A. Salama3, N. Aly Eldin4

Author affiliations

  • 1 Medical Oncology, national cancer institute cairo university, 11796 - Cairo/EG
  • 2 Surgical Oncology, national cancer institute cairo university, 11796 - Cairo/EG
  • 3 Pathology, national cancer institute cairo university, 11796 - Cairo/EG
  • 4 Biostatistic, national cancer institute cairo university, 11796 - Cairo/EG
More

Resources

Abstract 4618

Background

Neoadjuvant chemotherapy (NCT) using anthracycline - taxane based chemotherapy achieved better outcome and increase the rate of breast conservative surgery (BCS). This study evaluates the efficacy and safety profile of 4 cycles AC followed by 4 cycles of DC as NCT and detect pCR with its subsequent effect on BCS, OS, DFS and its correlation with molecular subtypes and other markers as ERCC1and Ki-67.

Methods

A prospective phase II study at the Medical Oncology Department of the National Cancer Institute (NCI), Cairo University, where 104 female patients with LABC were recruited during the period from March 2010 to July 2013 to receive eight cycles of NCT, 4 cycles of (AC) followed by 4 cycles of (DC), responding patients were referred to surgery then to radiotherapy for local control. All patients were assessable for toxicity. ER, PR, Her2neu, Ki-67 and ERCC1 were done.

Results

Median age: 51yrs, postmenopausal: 48.1%, median tumour size at presentation: 8 cm, stage IIIB: 82.7%, ER/PR positive: 78.8% and 25% were Her2neu positive. The pCR after DC according to Miller and Payne system was 20.2%, with mean tumour size:4.15± S.D 2.703. Age and menopausal status showed statistical significant correlation with pathological response. The correlation between DFS in positive and negative ERCC1 was statistically significant; (p-value ≤ 0.01). The overall survival (OS)of the patients was 85.4% at 36 months while the disease free survival (DFS) was 85.3% at 24 months. Anaemia G2 & more was encountered in 27 patients (26%); neutropenia G2 & more was reported in 49 patients (47.1%), while Peripheral neuritis was observed in 103 patients (99%).

Conclusions

Adding Cisplatin to Docetaxel for 4 cycles after 4 cycles of Adriamycin – Cyclophosphamide improved the pCR, OS and rate of BCS. ERCC1 is a predictor marker of DFS.

Clinical trial identification

Legal entity responsible for the study

IRB Committee of the national cancer institute of Cairo University

Funding

National Cancer Institute - Cairo University

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.